| Literature DB >> 29296695 |
Sara Serra1,2, Tiziana Vaisitti1,2, Valentina Audrito1,2, Cinzia Bologna1,2, Roberta Buonincontri1,2, Shih-Shih Chen3, Francesca Arruga1,2, Davide Brusa2, Marta Coscia4, Ozren Jaksic5, Giorgio Inghirami6,7, Davide Rossi8, Richard R Furman9, Simon C Robson10, Gianluca Gaidano8, Nicholas Chiorazzi3, Silvia Deaglio1,2.
Abstract
The chronic lymphocytic leukemia (CLL) niche is a closed environment where leukemic cells derive growth and survival signals through their interaction with macrophages and T lymphocytes. Here, we show that the CLL lymph node niche is characterized by overexpression and activation of HIF-1α, which increases adenosine generation and signaling, affecting tumor and host cellular responses. Hypoxia in CLL lymphocytes modifies central metabolic pathways, protects against drug-driven apoptosis, and induces interleukin 10 (IL-10) production. In myeloid cells, it forces monocyte differentiation to macrophages expressing IRF4, IDO, CD163, and CD206, hallmarks of the M2 phenotype, which promotes tumor progression. It also induces IL-6 production and enhances nurturing properties. Low oxygen levels decrease T-cell proliferation, promote glycolysis, and cause the appearance of a population of PD-1+ and IL-10-secreting T cells. Blockade of the A2A adenosine receptor counteracts these effects on all cell populations, making leukemic cells more susceptible to pharmacological agents while restoring immune competence and T-cell proliferation. Together, these results indicate that adenosine signaling through the A2A receptor mediates part of the effects of hypoxia. They also suggest that therapeutic strategies to inhibit the adenosinergic axis may be useful adjuncts to chemotherapy or tyrosine kinase inhibitors in the treatment of CLL patients.Entities:
Year: 2016 PMID: 29296695 PMCID: PMC5744057 DOI: 10.1182/bloodadvances.2016000984
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529